Interpace Biosciences, Inc. Common Stock
IDXG
IDXG was delisted on the 24th of February, 2021.
16 hedge funds and large institutions have $704K invested in Interpace Biosciences, Inc. Common Stock in 2017 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
14% more funds holding
Funds holding: 14 → 16 (+2)
28% less capital invested
Capital invested by funds: $984K → $704K (-$280K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$288K |
| 2 |
Morgan Stanley
New York
|
+$141K |
| 3 |
AS
Arxis Securities
New York
|
+$130K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$120K |
| 5 |
JP Morgan Chase
New York
|
+$50.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$292K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
-$108K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$64K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$1.72K |
IDXG Hedge Fund Activity: Q1 2017 in Review
16 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in Interpace Biosciences, Inc. Common Stock (IDXG) for Q1 2017, worth a combined $704K — down 28% from $984K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new IDXG positions and 3 closed out — a net gain of 4 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was BlackRock, opening a new position worth an estimated $288K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $292K sold.
- 16 institutional investors held Interpace Biosciences, Inc. Common Stock (IDXG) as of Q1 2017, up from 14 in Q4 2016.
- Funds reported $704K of Interpace Biosciences, Inc. Common Stock stock for Q1 2017, down 28% quarter-over-quarter.
- 7 funds opened new Interpace Biosciences, Inc. Common Stock positions in Q1 2017 and 3 closed out, a net change of +4 holders.
- The largest Interpace Biosciences, Inc. Common Stock buyer in Q1 2017 was BlackRock, an estimated $288K added.
- The largest Interpace Biosciences, Inc. Common Stock seller in Q1 2017 was Renaissance Technologies, an estimated $292K sold.
Based on aggregated 13F filings for Q1 2017.